MINDCURE to utilize patient data provided by ATMA to optimize iSTRYM, its digital therapeutics platform VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, announced today an exclusive data licensing agreement with ATMA Journey Centers Inc.


Previous articleMydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data
Next articleATMA Journey Centers Offer Regulated Health Care Professionals a Means to Incorporate Psychedelic-Assisted Psychotherapy Into Their Practice